Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy

NCT03050827 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Diabetic; Neuropathic, Polyneuropathy (Manifestation)

Interventions

DRUG: 3% oxybutynin
DRUG: Placebo

Sponsor

Eastern Virginia Medical School

Collaborators

[object Object]